labiotech20h
Curing ALS? Fourteen companies developing new treatments in 2025
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
PharmaTimes2d
Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
Zydus Life rises after USFDA grants orphan drug status to Usnoflast for ALS treatment
Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...
Pharmabiz2d
Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis
Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...
The Lancet2d
Transforming amyotrophic lateral sclerosis into a liveable disease
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...
devdiscourse3d
Zydus Strides Forward with Orphan Drug for ALS
Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...
ALS News Today3d
ALS Nexus 2025 event aiming to make disease ‘livable’ for patients
The ALS Association will host its second ALS Nexus conference in August, with the goal of making the disease a livable one ...
BioSpace3d
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...
Hosted on MSN3d
FDA lifts clinical hold on Amylyx’s Phase I ALS trial
This is the latest venture for Amylyx into the ALS field after its previous therapy Relyvrio was pulled from the market in ...
New Bedford man stole over $450K from disabled veteran. Here's what we know.
Hundreds of thousands in monthly veteran benefits were stolen by New Bedford man. Here's what he was sentenced: ...
FDA clears Amylyx to resume ALS drug trial in North America
CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...
Amylyx Says FDA Lifts Clinical Hold on ALS-Drug Trial
The company in March said its ALS drug Relyvrio had failed a late-stage clinical trial, and the stock has sunk more than 78% over the past year. Amylyx pulled Relyvrio from the market, cut its ...